Stoke Therapeutics (STOK) Receivables - Other (2018 - 2026)
Stoke Therapeutics' quarterly Receivables - Other came in at $1.7 million in Q1 2026, up 178.88% year-on-year from $606000.0 in Q1 2025, and down 14.17% quarter-over-quarter from $2.0 million in Q4 2025.
Stoke Therapeutics has reported Receivables - Other for 9 years, with the latest figure at $1.7 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Other rose 178.88% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 178.88% YoY), and the FY2025 full-year result was $2.0 million, up 181.29% from the prior year.
- Receivables - Other for Q1 2026 stood at $1.7 million, down from $2.0 million in the prior quarter.
- The five-year high for Receivables - Other was $2.0 million in Q4 2025, with the low at $11000.0 in Q1 2024.
- Average Receivables - Other over 5 years is $680529.4, with a median of $492000.0 recorded in 2023.
- Year-over-year, Receivables - Other plunged 97.76% in 2024 and jumped 5409.09% in 2025.
- Tracing STOK's Receivables - Other over 5 years: stood at $588000.0 in 2022, then tumbled by 89.12% to $64000.0 in 2023, then soared by 993.75% to $700000.0 in 2024, then jumped by 181.29% to $2.0 million in 2025, then dropped by 14.17% to $1.7 million in 2026.
- The last three Receivables - Other figures came in at $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.69 Mn |
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 606,000.00 |
| Mar 31, 2025 | 606,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Dec 31, 2024 | 700,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Sep 30, 2023 | 96,000.00 |
| Sep 30, 2023 | 96,000.00 |
| Jun 30, 2023 | 136,000.00 |
| Jun 30, 2023 | 136,000.00 |
| Mar 31, 2023 | 492,000.00 |
| Mar 31, 2023 | 492,000.00 |
| Dec 31, 2022 | 588,000.00 |
| Dec 31, 2022 | 588,000.00 |
| Sep 30, 2022 | 395,000.00 |
| Sep 30, 2022 | 395,000.00 |
| Jun 30, 2022 | 350,000.00 |
| Jun 30, 2022 | 350,000.00 |
| Mar 31, 2022 | 265,000.00 |
| Mar 31, 2022 | 265,000.00 |
| Dec 31, 2021 | 132,000.00 |
| Dec 31, 2021 | 132,000.00 |
| Sep 30, 2021 | 45,000.00 |
| Sep 30, 2021 | 45,000.00 |
| Jun 30, 2021 | 131,000.00 |
| Jun 30, 2021 | 131,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 144,000.00 |
| Mar 31, 2020 | 144,000.00 |
| Dec 31, 2019 | 281,000.00 |
| Dec 31, 2019 | 281,000.00 |
| Sep 30, 2019 | 376,000.00 |
| Sep 30, 2019 | 376,000.00 |
| Jun 30, 2019 | 260,000.00 |
| Jun 30, 2019 | 260,000.00 |
| Dec 31, 2018 | 196,000.00 |
| Dec 31, 2018 | 196,000.00 |